Concise review: Review and perspective of cell dosage and routes of administration from preclinical and clinical studies of stem cell therapy for heart disease

Samuel Golpanian, Ivonne H Schulman, Ray F. Ebert, Alan W. Heldman, Darcy L. Difede, Phillip C. Yang, Joseph C. Wu, Roberto Bolli, Emerson C. Perin, Lem Moyé, Robert D. Simari, Ariel Wolf, Joshua Hare

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

An important stage in the development of any new therapeutic agent is establishment of the optimal dosage and route of administration. This can be particularly challenging when the treatment is a biologic agent that might exert its therapeutic effects via complex or poorly understood mechanisms. Multiple preclinical and clinical studies have shown paradoxical results, with inconsistent findings regarding the relationship between the cell dose and clinical benefit. Such phenomena can, at least in part, be attributed to variations in cell dosing or concentration and the route of administration (ROA). Although clinical trials of cell-based therapy for cardiovascular disease began more than a decade ago, specification of the optimal dosage and ROA has not been established. The present review summarizes what has been learned regarding the optimal cell dosage and ROA from preclinical and clinical studies of stem cell therapy for heart disease and offers a perspective on future directions.

Original languageEnglish (US)
Pages (from-to)186-191
Number of pages6
JournalStem cells translational medicine
Volume5
Issue number2
DOIs
StatePublished - 2016

Fingerprint

Cell- and Tissue-Based Therapy
Heart Diseases
Stem Cells
Biological Factors
Therapeutic Uses
Cardiovascular Diseases
Clinical Trials
Therapeutics
Clinical Studies

Keywords

  • Cardiovascular disease
  • Cell dosage
  • Route of administration
  • Stem cell

ASJC Scopus subject areas

  • Cell Biology
  • Developmental Biology

Cite this

Concise review : Review and perspective of cell dosage and routes of administration from preclinical and clinical studies of stem cell therapy for heart disease. / Golpanian, Samuel; Schulman, Ivonne H; Ebert, Ray F.; Heldman, Alan W.; Difede, Darcy L.; Yang, Phillip C.; Wu, Joseph C.; Bolli, Roberto; Perin, Emerson C.; Moyé, Lem; Simari, Robert D.; Wolf, Ariel; Hare, Joshua.

In: Stem cells translational medicine, Vol. 5, No. 2, 2016, p. 186-191.

Research output: Contribution to journalArticle

Golpanian, Samuel ; Schulman, Ivonne H ; Ebert, Ray F. ; Heldman, Alan W. ; Difede, Darcy L. ; Yang, Phillip C. ; Wu, Joseph C. ; Bolli, Roberto ; Perin, Emerson C. ; Moyé, Lem ; Simari, Robert D. ; Wolf, Ariel ; Hare, Joshua. / Concise review : Review and perspective of cell dosage and routes of administration from preclinical and clinical studies of stem cell therapy for heart disease. In: Stem cells translational medicine. 2016 ; Vol. 5, No. 2. pp. 186-191.
@article{52caa337e6cc46d79185491cc642f569,
title = "Concise review: Review and perspective of cell dosage and routes of administration from preclinical and clinical studies of stem cell therapy for heart disease",
abstract = "An important stage in the development of any new therapeutic agent is establishment of the optimal dosage and route of administration. This can be particularly challenging when the treatment is a biologic agent that might exert its therapeutic effects via complex or poorly understood mechanisms. Multiple preclinical and clinical studies have shown paradoxical results, with inconsistent findings regarding the relationship between the cell dose and clinical benefit. Such phenomena can, at least in part, be attributed to variations in cell dosing or concentration and the route of administration (ROA). Although clinical trials of cell-based therapy for cardiovascular disease began more than a decade ago, specification of the optimal dosage and ROA has not been established. The present review summarizes what has been learned regarding the optimal cell dosage and ROA from preclinical and clinical studies of stem cell therapy for heart disease and offers a perspective on future directions.",
keywords = "Cardiovascular disease, Cell dosage, Route of administration, Stem cell",
author = "Samuel Golpanian and Schulman, {Ivonne H} and Ebert, {Ray F.} and Heldman, {Alan W.} and Difede, {Darcy L.} and Yang, {Phillip C.} and Wu, {Joseph C.} and Roberto Bolli and Perin, {Emerson C.} and Lem Moy{\'e} and Simari, {Robert D.} and Ariel Wolf and Joshua Hare",
year = "2016",
doi = "10.5966/sctm.2015-0101",
language = "English (US)",
volume = "5",
pages = "186--191",
journal = "Stem cells translational medicine",
issn = "2157-6564",
publisher = "AlphaMed Press",
number = "2",

}

TY - JOUR

T1 - Concise review

T2 - Review and perspective of cell dosage and routes of administration from preclinical and clinical studies of stem cell therapy for heart disease

AU - Golpanian, Samuel

AU - Schulman, Ivonne H

AU - Ebert, Ray F.

AU - Heldman, Alan W.

AU - Difede, Darcy L.

AU - Yang, Phillip C.

AU - Wu, Joseph C.

AU - Bolli, Roberto

AU - Perin, Emerson C.

AU - Moyé, Lem

AU - Simari, Robert D.

AU - Wolf, Ariel

AU - Hare, Joshua

PY - 2016

Y1 - 2016

N2 - An important stage in the development of any new therapeutic agent is establishment of the optimal dosage and route of administration. This can be particularly challenging when the treatment is a biologic agent that might exert its therapeutic effects via complex or poorly understood mechanisms. Multiple preclinical and clinical studies have shown paradoxical results, with inconsistent findings regarding the relationship between the cell dose and clinical benefit. Such phenomena can, at least in part, be attributed to variations in cell dosing or concentration and the route of administration (ROA). Although clinical trials of cell-based therapy for cardiovascular disease began more than a decade ago, specification of the optimal dosage and ROA has not been established. The present review summarizes what has been learned regarding the optimal cell dosage and ROA from preclinical and clinical studies of stem cell therapy for heart disease and offers a perspective on future directions.

AB - An important stage in the development of any new therapeutic agent is establishment of the optimal dosage and route of administration. This can be particularly challenging when the treatment is a biologic agent that might exert its therapeutic effects via complex or poorly understood mechanisms. Multiple preclinical and clinical studies have shown paradoxical results, with inconsistent findings regarding the relationship between the cell dose and clinical benefit. Such phenomena can, at least in part, be attributed to variations in cell dosing or concentration and the route of administration (ROA). Although clinical trials of cell-based therapy for cardiovascular disease began more than a decade ago, specification of the optimal dosage and ROA has not been established. The present review summarizes what has been learned regarding the optimal cell dosage and ROA from preclinical and clinical studies of stem cell therapy for heart disease and offers a perspective on future directions.

KW - Cardiovascular disease

KW - Cell dosage

KW - Route of administration

KW - Stem cell

UR - http://www.scopus.com/inward/record.url?scp=84969443678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969443678&partnerID=8YFLogxK

U2 - 10.5966/sctm.2015-0101

DO - 10.5966/sctm.2015-0101

M3 - Article

C2 - 26683870

AN - SCOPUS:84969443678

VL - 5

SP - 186

EP - 191

JO - Stem cells translational medicine

JF - Stem cells translational medicine

SN - 2157-6564

IS - 2

ER -